奥司他韦治疗甲型流感的临床研究进展

Progress of Oseltamivir in the Treatment of Influenza A

奥司他韦是目前临床上最常用的抗甲型流感病毒药。但是,世界卫生组织在2017年更新基本药物目录清单时将奥司他韦由核心用药降为辅助用药,并考虑在下一期目录中删除该药。而各国关于流感病毒的最新指南中仍然推荐奥司他韦为一线药物,推荐在发病48 h内尽早应用,且有部分研究推荐重症患者采用大剂量疗法。本文就世界卫生组织及各国指南的不同决策进行相应的文献回顾性分析,分析奥司他韦降级及推荐的循证医学证据,并对重症患者的治疗剂量进行相应探讨。

Oseltamivir is one of the most commonly used anti-influenza A virus drugs in clinic.However,when the World Health Organization updated the list of essential medicines in 2017,oseltamivir was adjusted from the core drug to the auxiliary drug,and oseltamivir was considered to be deleted in the next issue of the list.The latest guidelines in various countries still recommended oseltamivir as the first-line drug,and which was recommended to be applied as soon as possible within 48 h after onset,some studies recommended high-dose therapy for patients in severe cases.This paper retrospectively analyzes the relevant literature on the different decisions made by WHO and national guidelines,summarizes the evidence-based medical evidence for the downgrade of oseltamivir and the recommendation of oseltamivir,and discusses the corresponding therapeutic dose for patients in severe cases.